SRPT logo

SRPT
Sarepta Therapeutics Inc

26,749
Mkt Cap
$1.76B
Volume
2.62M
52W High
$107.77
52W Low
$10.42
PE Ratio
-1.99
SRPT Fundamentals
Price
$16.76
Prev Close
$17.45
Open
$17.17
50D MA
$20.47
Beta
1.19
Avg. Volume
3.18M
EPS (Annual)
-$7.13
P/B
1.55
Rev/Employee
$1.6M
$2,243.28
Loading...
Loading...
News
all
press releases
Sarepta Therapeutics (NASDAQ:SRPT) Stock Rating Upgraded by Wall Street Zen
Wall Street Zen upgraded shares of Sarepta Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday...
MarketBeat·2d ago
News Placeholder
More News
News Placeholder
Wells Fargo & Company Cuts Sarepta Therapeutics (NASDAQ:SRPT) Price Target to $38.00
Wells Fargo & Company decreased their price objective on shares of Sarepta Therapeutics from $45.00 to $38.00 and set an "overweight" rating on the stock in a research report on Friday...
MarketBeat·2d ago
News Placeholder
Sarepta Therapeutics Stock: A Deep Dive Into Analyst Perspectives (5 Ratings)
read more...
Benzinga·2d ago
News Placeholder
Sarepta Therapeutics Announces Call for Applications for the 9th Annual Route 79, The Duchenne Scholarship Program
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced the official opening of Route 79, The Duchenne Scholarship Program for the...
Business Wire·2d ago
News Placeholder
Erste Asset Management GmbH Has $50.59 Million Stock Position in Sarepta Therapeutics, Inc. $SRPT
Erste Asset Management GmbH boosted its position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 65.7% in the 3rd quarter, according to its most recent filing with the...
MarketBeat·3d ago
News Placeholder
Sarepta Therapeutics (NASDAQ:SRPT) Stock Price Down 9% Following Weak Earnings
Sarepta Therapeutics (NASDAQ:SRPT) Stock Price Down 9% Following Weak Earnings...
MarketBeat·3d ago
News Placeholder
Sarepta Q4 Loss Wider Than Expected, Sales Beat Estimates
SRPT posts a wider Q4 loss as Elevidys sales tumble, but revenues top estimates and 2026 guidance outlines a cautious recovery path.
Zacks·3d ago
News Placeholder
Compared to Estimates, Sarepta Therapeutics (SRPT) Q4 Earnings: A Look at Key Metrics
Although the revenue and EPS for Sarepta Therapeutics (SRPT) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Zacks·3d ago
News Placeholder
Sarepta Therapeutics to Present New Long-Term and Safety Data Across Gene Therapy and Exon-Skipping Programs at 2026 Muscular Dystrophy Association Clinical & Scientific Congress
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will present at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference, taking...
Business Wire·3d ago
News Placeholder
Rhumbline Advisers Sells 88,893 Shares of Sarepta Therapeutics, Inc. $SRPT
Rhumbline Advisers trimmed its position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 33.3% during the third quarter, according to its most recent disclosure with the...
MarketBeat·4d ago
<
1
2
...
>

Latest SRPT News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.